Over thirty-five years of experience in the pharmaceutical industry with increasing levels of responsibility held in positions across the drug development and discovery spectrum. Retired from Astellas Pharma Inc. as a Senior Vice President and Global Therapeutic Head for Oncology at Astellas Pharma Inc. In five years at Astellas, helped build Oncology into a global business with several marketed products including Tarceva® and Xtandi® and help build a robust oncology pipeline through in-licensing, the acquisition of OSI, and through internal discovery. Successful filings of NDAs and MAAs for Xtandi (enzalutamide) and Tarceva (sNDA). Previous experience as acting head of Oncology Clinical Sciences at Takeda Global R&D and Executive Director of Oncology Drug Development at Pfizer, Inc. At Takeda, led both early and late-stage Development Teams in Oncology. At Pfizer, led Development Teams from mid-Discovery through POC with additional experience in NDA filing of pentostatin/Nipent®. Led development teams at Pfizer and Parke-Davis to more than 14 successful IND filings and Phase 1 starts. Also led late stage programs in biologics including monoclonal antibodies and an oncolytic adenovirus. Prior to experience in drug development for oncology, led discovery efforts at Warner-Lambert/Parke Davis Pharmaceutical Research in oncology for 16 years in a number of areas including antiangiogenic agents, multiple drug resistance, histone deacetylase inhibitors, and antifolates.
Dr. Wayne Klohs
